90
Participants
Start Date
September 15, 2021
Primary Completion Date
March 15, 2024
Study Completion Date
March 15, 2024
AXS-12 (reboxetine)
AXS-12 tablets, taken twice daily
Placebo
Placebo tablets, taken twice daily
Clinical Research Site, New Hyde Park
Clinical Research Site, Brooklyn
Clinical Research Site, Wyomissing
Clinical Research Site, Chevy Chase
Clinical Research Site, Williamsburg
Clinical Research Site, Denver
Clinical Research Site, Gastonia
Clinical Research Site, Huntersville
Clinical Research Site, Columbia
Clinical Research Site, Charleston
Clinical Research Site, Stockbridge
Clinical Research Site, Atlanta
Clinical Research Site, Atlanta
Clinical Research Site, Gainesville
Clinical Research Site, Macon
Clinical Research Site, Winter Park
Clinical Research Site, Miami Lakes
Clinical Research Site, Doral
Clinical Research Site, Miami
Clinical Research Site, Brandon
Clinical Research Site, Tampa
Clinical Research Site, St. Petersburg
Clinical Research Site, Clearwater
Clinical Research Site, Kissimmee
Clinical Research Site, Alabaster
Clinical Research Site, Cincinnati
Clinical Research Site, Fort Wayne
Clinical Research Site, Novi
Clinical Research Site, Kalamazoo
Clinical Research Site, Peoria
Clinical Research Site, Maplewood
Clinical Research Site, Sugar Land
Clinical Research Site, San Antonio
Clinical Research Site, Austin
Clinical Research Site, Boulder
Clinical Research Site, Colorado Springs
Clinical Research Site, Phoenix
Clinical Research Site, Peoria
Clinical Research Site, Las Vegas
Clinical Research Site, Santa Monica
Clinical Research Site, San Diego
Clinical Research Site, Santa Ana
Clinical Research Site, Redwood City
Clinical Research Site, Honolulu
Clinical Research Site, Newton
Clinical Research Site, North Dartmouth
Clinical Research Site, West Long Branch
Clinical Research Site, Markham
Clinical Research Site, Toronto
Clinical Research Site, Toronto
Lead Sponsor
Axsome Therapeutics, Inc.
INDUSTRY